Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Disposition of /sup 14/C tolrestat in laboratory animals and man

Conference · · Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States)
OSTI ID:5320593

The disposition of the aldose reductase inhibitor tolrestat (T) was determined in the mouse, rat, dog, assemensis monkey, and man. Serum T and radioactivity ratios, and % of dose excreted after p.o. administration of /sup 14/C-T at a dose of 10 mk/kg (100 mg to man), are presented. Except for the rat and monkey, 55 to 95% of the urinary /sup 14/C was due to T and oxo-tolrestat (oxo-T, N-((5-(trifluoromethyl)-6-methoxy-1-napthalenyl)oxo-methyl)-N-methylglycine). Oxo-T is formed, in part, non-enzymatically from T; a potential intermediate in this transformation was detected in all the urine samples. In man and monkey, about 15% and 68%, respectively, of the urinary /sup 14/C was due to T-glucuronide. In rat urine, >90% of the /sup 14/C was due to polar metabolites; in bile, about 66% of the /sup 14/C was due to T. The composition of the serum /sup 14/C in the mouse and rat was determined. In conclusion, /sup 14/C-T was rapidly and well absorbed by all species. Except for the rat and dog, urine was the main excretion route for /sup 14/C. Urine/sup 14/ comprised mainly T, t-glucuronide of oxo-T in all the species except the rat.

Research Organization:
Ayerst Labs. Research Inc., Princeton, NJ
OSTI ID:
5320593
Report Number(s):
CONF-8604222-
Journal Information:
Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States), Journal Name: Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States) Vol. 45:3; ISSN FEPRA
Country of Publication:
United States
Language:
English